Caribou Biosciences Inc CRBU

$1.22 0.00 (—)

Valuation

Market cap: 130,794,000
Revenue TTM: $11,160,000
Net income TTM: $-148,130,000
PE ratio: 0.00
Forward PE: —
Profit margin: -1,327.33%
Debt to equity: 0.00

Trading

Volume: 866,500
Avg volume: 1,088,876
Day's range: $1.22 – $1.24
Shares out: 107,208,000
Stochastic %K: 3%
Beta: 2.31
Analysts: Strong Sell
Price target: $11.86

Price

Company profile

Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

Industry: Biotechnology
Sector: Healthcare
Phone: 510 982 6030
Website: https://cariboubio.com
Address: 2929 7th Street, Suite 105, Berkeley, United States

Latest news

2026-08-16T14:03:44.000Z · 6 weeks ago

Caribou Biosciences reports Q2 EPS (24c), consensus (31c)

2026-08-16T13:45:19.000Z · 6 weeks ago

Caribou Biosciences price target lowered to $5 from $6 at BofA

Aug 13, 2026, 4:05 PM EDT · 7 weeks ago

Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update

Jun 29, 2026, 8:00 AM EDT · 3 months ago

Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

2026-06-11T13:03:22.000Z · 3 months ago

Caribou Biosciences presents ANTLER trial results at EHA

Jun 11, 2026, 8:01 AM EDT · 3 months ago

Caribou Biosciences Reports Long-Term Vispa-cel Data in Second-line Large B Cell Lymphoma at EHA 2026

Jun 11, 2026, 8:00 AM EDT · 3 months ago

Caribou Biosciences Reports Dose Escalation Durability Data for CB-011 at the 2026 European Hematology Association (EHA) Annual Meeting

May 27, 2026, 4:05 PM EDT · 4 months ago

Caribou Biosciences to Participate in the 2026 Jefferies Global Healthcare Conference

May 13, 2026, 4:05 PM EDT · 4 months ago

Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference

May 12, 2026, 9:30 AM EDT · 4 months ago

Caribou Biosciences to Highlight Vispa-cel and CB-011 Programs During Oral Presentations at the 2026 European Hematology Association (EHA) Annual Meeting

2026-05-11T10:25:24.000Z · 4 months ago

Caribou Biosciences price target raised to $11 from $9 at H.C. Wainwright

May 7, 2026, 4:05 PM EDT · 4 months ago

Caribou Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update

May 5, 2026, 4:05 PM EDT · 5 months ago

Caribou Biosciences to Participate in the BofA Securities 2026 Health Care Conference

Mar 31, 2026, 8:00 AM EDT · 6 months ago

Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy

2026-03-09T12:14:17.000Z · 6 months ago

Caribou Biosciences price target raised to $13 from $11 at Evercore ISI

2026-03-05T21:28:29.000Z · 7 months ago

Caribou Biosciences reports Q4 EPS (28c) vs. (39c) last year

Mar 5, 2026, 4:05 PM EST · 7 months ago

Caribou Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Feb 17, 2026, 8:00 AM EST · 7 months ago

Watchmaker Genomics Licenses CRISPR-Cas9 Intellectual Property from Caribou Biosciences to Increase Throughput and Reduce Sequencing Cost per Sample

Feb 12, 2026, 4:05 PM EST · 7 months ago

Caribou Biosciences to Participate in Upcoming Investor Conferences

Feb 4, 2026, 8:00 AM EST · 8 months ago

Caribou Biosciences Announces Late-Breaking Presentations at the 2026 Tandem Meetings of ASTCT® and CIBMTR®

2026-02-02T21:25:29.000Z · 8 months ago

Caribou Biosciences initiated with a Buy at Clear Street

2026-01-06T15:15:25.000Z · 9 months ago

Caribou Biosciences price target lowered to $6 from $8 at BofA

Dec 1, 2025, 4:05 PM EST · 10 months ago

Caribou Biosciences to Host In-Person and Virtual KOL Event at ASH 2025

2025-11-12T22:25:13.000Z · 10 months ago

Caribou Biosciences reports Q3 EPS (30c) vs. (38c) last year

Nov 12, 2025, 4:05 PM EST · 10 months ago

Caribou Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update

2025-11-05T11:21:02.000Z · 11 months ago

Caribou Biosciences price target raised to $9 from $3 at H.C. Wainwright

2025-11-03T15:15:34.000Z · 11 months ago

Caribou Biosciences price target raised to $8 from $5 at Citi

2025-11-03T12:22:51.000Z · 11 months ago

Caribou Biosciences announces results from CaMMouflage Phase 1 trial

2025-11-03T12:15:12.000Z · 11 months ago

Caribou Biosciences announces results from ANTLER phase 1 trial of vispa-cel

Nov 3, 2025, 7:00 AM EST · 11 months ago

Caribou Biosciences Announces Positive Data from CaMMouflage Phase 1 Trial of CB-011 in Multiple Myeloma

Nov 3, 2025, 7:00 AM EST · 11 months ago

Caribou Biosciences Announces Positive Data from ANTLER Phase 1 Trial Demonstrating Efficacy and Durability of Vispa-cel (CB-010), an Allogeneic CAR-T Cell Therapy, on Par with Autologous CAR-T Cell Therapies

Nov 2, 2025, 4:00 PM EST · 11 months ago

Caribou Biosciences to Host Webcast to Report New Data Updates from Two Allogeneic CAR-T Cell Therapy Programs in Lymphoma and Multiple Myeloma

Aug 25, 2025, 4:05 PM EDT · 1 year ago

Caribou Biosciences to Participate in the Citi 2025 Biopharma Back to School Conference

Aug 12, 2025, 4:05 PM EDT · 1 year ago

Caribou Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Update

May 28, 2025, 4:00 PM EDT · 1 year ago

Caribou Biosciences to Participate in the Jefferies Global Healthcare Conference

May 8, 2025, 4:05 PM EDT · 1 year ago

Caribou Biosciences Reports First Quarter 2025 Financial Results and Provides Business Update

May 6, 2025, 4:00 PM EDT · 1 year ago

Caribou Biosciences to Participate in the BofA Securities 2025 Health Care Conference

Apr 24, 2025, 4:15 PM EDT · 1 year ago

Caribou Biosciences Announces Strategic Pipeline Prioritization with Focus on CB-010 and CB-011 Oncology Programs

Mar 10, 2025, 4:05 PM EDT · 1 year ago

Caribou Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Stocktwits

Gyrdahl Oct 1, 11:48 AM

$CRBU Does anyone know why this crbu is up 10.24% according to stocktwits? No premarket trades on tradingview...

1 replies

HughGeez Sep 30, 8:50 PM

$CRBU Interesting thought. People donate money on GoFundMe to strangers who have cancer, but don't invest in a company making massive strides to cure cancer and make treatments more accessible... with the possibility of making huge gains on their investment. I don't get it either! Although I do think time will sort it out.

1 replies